Shanghai‑based Unixell Biotech received FDA clearance to start a Phase 1 trial of UX‑GIP001, an iPSC‑derived, allogeneic cell therapy for focal epilepsy resistant to drugs. The first‑in‑human study will evaluate safety and tolerability in patients with drug‑resistant focal seizures and aims to establish a clinical path for cell replacement or modulatory approaches in refractory epilepsy. The IND signals growing U.S. regulatory receptivity to pluripotent stem‑cell–derived therapeutic candidates and adds to a wave of cell therapy programs pursuing neurological indications. Source: Unixell announcement and regulatory filing notice.